Shares of Pozen Inc. (POZN) rallied nearly 10% to $8.00 in the pre-market session Monday after the company released its earnings results. The firm reported Q4/14 EPS of $0.21 per share vs. $0.15 consensus on $9.90 million in revenue vs. $8.55 million consensus, up 110.6% from a year ago. The pharmaceutical company said Q4 2014 was the fourth consecutive profitable quarter.
For the year ended 2014, Pozen reported total revenue of $32.4 million, compared to $10.3 million in FY 2013. Operating expenses totaled $15.8 million, as compared to $27.1 million for the comparable period in 2013.
On valuation measures, Pozen Inc. shares, which currently have an average 3-month trading volume of 402K shares, trade at a trailing-12 P/E of 22.19, a forward P/E of 10.00 and a P/E to growth ratio of 0.44. The median Wall Street price target on the name is $10.50 with a high target of $11.00. Currently ticker boasts 2 ‘Buy’ endorsements, compared to no ’Holds’ and no ‘Sell’.
Profitability-wise, POZN has a t-12 profit and operating margin of 38.56% and 27.98%, respectively. The $234.16 million market cap company reported $43.3 million in cash vs. $3.7 million in total current liabilities in its most recent quarter.
POZN currently prints a one year loss of about 11% and a year-to-date loss of around 9%.
Pozen Inc. develops products for the treatment of acute and chronic pain, and pain related conditions in the U.S.and internationally. The company was founded in 1996 and is headquartered in Chapel Hill, North Carolina.